Montag A & Associates Inc. Cuts Stake in IQVIA Holdings Inc. (NYSE:IQV)

Montag A & Associates Inc. trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 31.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,031 shares of the medical research company’s stock after selling 7,638 shares during the quarter. Montag A & Associates Inc.’s holdings in IQVIA were worth $3,347,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of IQV. FMR LLC lifted its holdings in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the period. Impax Asset Management Group plc grew its stake in IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after acquiring an additional 157,809 shares in the last quarter. Nordea Investment Management AB grew its stake in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of IQVIA by 3.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock valued at $290,545,000 after buying an additional 39,772 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the transaction, the director now owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on IQV shares. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Barclays lowered their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Bank of America dropped their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $251.67.

IQVIA Price Performance

Shares of NYSE IQV opened at $193.65 on Monday. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a 50-day simple moving average of $200.41 and a 200-day simple moving average of $218.02. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The stock has a market capitalization of $35.15 billion, a price-to-earnings ratio of 25.82, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.